Lantern Pharma Inc. (LTRN) Stock

Lantern Pharma Inc. (LTRN) is a Healthcare stock trading at $2.36 (as of 2026-08-21), with a market capitalization of $30.17M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Understand Lantern Pharma Inc.: how it makes money

Lantern Pharma is a clinical-stage biotech developing AI and genomics enabled cancer drugs, aiming to turn its platform and trial data from candidates like LP-100 and LP-300 into future development and commercialization opportunities.

The profit model is fundamentally tied to producing and validating clinical and molecular data through its AI, machine learning, and genomic approach as it advances oncology candidates such as LP-100 in phase II and LP-300 in phase II, plus preclinical work on LP-184.

Business quality (Weak): Clearly focused oncology pipeline with phase II activity and multiple trial outcome metrics tracked, but near term value depends on clinical validation across programs that are still in development.

Bull case

AI and genomic data are integrated into the drug development process: The company uses its Radar Artificial Intelligence Platform, with large volumes of oncology focused data points and molecular screening activity, to support treatment response prediction and clinical development decisions.
LP-300 has reported lead-in clinical outcomes that the company highlights: LP-300 lead-in results show clinical benefit rate and objective response rate in the LP-300 lead-in cohort, and the company also reports similar lead-in metrics for the LP-300 Harmonic Trial.

Bear case

Clinical-stage execution risk remains high: The pipeline includes phase II programs (LP-100 and LP-300) and a preclinical candidate (LP-184), so progress depends on outcomes that may not carry through to later development stages.
Operational capacity may be constrained by team size: With a small company team size and a limited number of employees focused on drug development, biology, and data science efforts, execution bandwidth could be a constraint.

Valuation — source: SEC EDGAR (first-party)
Price	$2.36
Market Cap	$30.17M
FCF Yield	-42.7%

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BIOS Capital Management, LP ($1.18M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Panna Sharma
Employees	24
Country	US
IPO Date	2020-06-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.